Law360, New York (January 08, 2008) -- King Pharmaceuticals Inc. has dropped one of the infringement cases concerning its muscle relaxant Skelaxin, agreeing to grant a patent license allowing the defendant, CorePharma LLC, to manufacture a generic version of the drug, known as metaxalone, beginning in 2012.
In a filing with the U.S. Securities and Exchange Commission on Jan. 8, King announced it settled its case against CorePharma in the U.S. District Court for the Eastern District...
